Related Experiment Videos
Abnormal B cell function in haemophiliacs and their relationship with factor concentrates administration
Clinical and Experimental Immunology
|February 1, 1985
Summary
Clotting factor concentrates used in hemophilia treatment may impair B cell function. Patients receiving these concentrates showed altered immunoglobulin production, suggesting a link between treatment and immune response changes.
Area of Science:
- Immunology
- Hematology
Background:
- Hemophilia is a genetic bleeding disorder.
- B cell function is crucial for adaptive immunity.
Purpose of the Study:
- To evaluate B cell function in hemophiliacs.
- To investigate the impact of clotting factor concentrates on B cell activity.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure immunoglobulin (Ig) production.
- Peripheral blood lymphocytes (PBL) from hemophiliacs and normal donors were cultured.
- Allogeneic co-cultures of B and T cell fractions were performed.
Main Results:
- Spontaneous IgM, IgA, and IgG production was elevated in hemophiliacs compared to controls.
- Pokeweed mitogen (PWM)-induced Ig production was significantly reduced in hemophiliacs.
- Defects in T cell-depleted fractions of hemophiliacs' lymphocytes were identified.
- These abnormalities were absent in patients not receiving clotting factor concentrates.
- Clotting factor concentrate administration correlated with altered Ig production and serum IgG levels.
Conclusions:
- Clotting factor concentrates appear to play a role in the altered B cell function observed in hemophiliacs.
- Further research is needed to understand the mechanisms underlying these effects.